The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Palonosetron (PALO) plus 1-day versus 3-day dexamethasone (DEX) with or without aprepitant against delayed nausea (DN): Pooled analysis for 554 women receiving highly emetogenic chemotherapy (HEC).
Luigi Celio
Consultant or Advisory Role - Helsinn Therapeutics
Flavia Longo
No relevant relationships to disclose
Giovanni Mansueto
No relevant relationships to disclose
Vittoria Lapadula
No relevant relationships to disclose
Francesco Agustoni
No relevant relationships to disclose
Matti S. Aapro
Consultant or Advisory Role - Helsinn Therapeutics